Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method t...

Full description

Bibliographic Details
Main Authors: María José Germanó, Esteban Sebastián Lozano, María Victoria Sanchez, Flavia Alejandra Bruna, María Fernanda García-Bustos, Arianna Lourdes Sosa Lochedino, María Cristina Salomón, Ana Paula Fernandes, Juan Pablo Mackern-Oberti, Diego Esteban Cargnelutti
Format: Article
Language:English
Published: Fundação Oswaldo Cruz (FIOCRUZ) 2020-07-01
Series:Memorias do Instituto Oswaldo Cruz
Subjects:
L. amazonensis
whole-cell vaccine
Poly (I:C)
leishmaniasis
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762020000100328&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762020000100328&tlng=en

Similar Items